

CORRESPONDENCE

Comment on “Commercial landscape of noninvasive prenatal testing in the United States”

We read with interest the recent review in *Prenatal Diagnosis* entitled “Commercial landscape of noninvasive prenatal testing in the United States” by Ashwin Agarwal *et al.*¹ We appreciate the attention afforded to the business and intellectual property landscape given by noninvasive prenatal testing’s rapid evolution. However, Agarwal *et al.* misrepresented the current commercial turnaround time for Natera’s single nucleotide polymorphism based Panorama™ test. This is an important parameter that affects clinical implementation, and as such, we feel it is important to report the most up-to-date information. We thus wish to communicate the preliminary results of analysis of the most recent 10000 commercially-processed samples.

Specifically, Panorama now reports a turnaround time of 5 to 10 business days; >95% of the aforementioned commercial samples were processed in under 10 business days.

Matthew Rabinowitz

Natera Inc., San Carlos, CA, USA

Correspondence to: Matthew Rabinowitz. E-mail: mrabinowitz@natera.com

Funding sources: None

Conflicts of interest: None declared

REFERENCE

1. Agarwal A, Sayres LC, Cho MK, Cook-Deegan R, Chandrasekharan S. Commercial landscape of noninvasive prenatal testing in the United States. *Prenat Diagn* 2013;33:521–31.